Application of the principles of corporate governance in agriculture cooperatives

The principles of corporate governance in the global economies and in the process of globalization are recognized and stated as extremely important, first in the successful business of companies and gaining competitiveness on the market, and then in the successful resolution of possible conflicts and conflicts of different interest groups within the companies themselves. However, can corporate governance principles be applied in agricultural cooperatives, which now, more than ever, require a good organization, the structure of the rules on which they will be more organized on the market and represent the interests of their cooperatives? By analyzing the cooperative sector, it's been attempted to integrate the principles of corporate governance, with the functioning of agricultural cooperatives, their basic values, organization, traditional organization, etc. in a way that they do not stand one against the other, but one in the function of the other, as a mutual complement

Analysis of the frequency and characteristics of the most common predictors of anxiety in adolescents

Anxiety represents the behavioral, emotional and cognitive response of the person on experience if potential or future danger. Pathological anxiety occurs when this reaction is unreasonable, that is it is not proportionate to the stress or challenge, and it leads to intense fear, nervousness and impaired functioning. Anxiety can occur in any period of life. Adolescence is a turbulent developmental period that increases the risk of young people to develop numerous mental disorders. Numerous predictors determinate the development of anxiety in adolescents. Prevention of anxiety disorders in adolescents is a public health priority, therefore it is necessary to identify risk factors and implement activities to suppress these factors

Naphthalan oil in the treatment of psoriasis and psoriatic arthritis

Background Naphthalan is a specific form of medicinal earth oil, and a number of subtypes are used in topical therapy for psoriasis and psoriatic arthritis. In the present study, yellow naphthalan oil that is enriched with steranes but that has a reduced content of polyaromatics was used. Objective The aim of the study was to assess the effect of naphthalan on psoriatic skin lesions, on painful and swollen joints, and on functional status of patients with psoriatic arthritis. Methods The study included 28 patients with chronic stationary psoriasis (psoriasis vulgaris) and 12 patients with psoriatic arthritis. Results In the psoriasis vulgaris study arm, the mean ± SD Psoriasis Area and Severity Index score was 23.1 ± 7.5 at baseline; it was 7.95 ± 4.08 after 3 weeks of naphthalan treatment. In the majority of patients, naphthalan treatment reduced articular pain and edema and improved mobility of affected joints. Conclusion Naphthalan provides efficacious therapy in the management of mild to moderate psoriasis and psoriatic arthritis. </jats:sec

Sigurnost i učinkovit ostfiksne kombinacije (travoprost 0,004%/timolol 0,5%) umjesto monoterapije u šestomjesečnom periodu praćenja

Purpose: To assess the safety and efficacy of changing antiglaucoma therapy to the travoprost 0,004%/timolol 0,5% (TTF C) fixed combination from previous monotherapies. Methods: Prospective, open-label, observational, multicenter cohort. A change was done from prior monotherapy at day 0 to TTF C dosed once a day, regardless in the evening or in the morning, without washout period. Active evaluation of systemic and local tolerability (adverse events), and efficacy ie. intraocular pressure (IOP) lowering was done at control 1 (day 30), control 2 (day 90) and control 3 (day 120). Results: 40/155/170 patients (79/309/339 eyes) completed the study (120 days/ 90 days/baseline, respectfully). At control 1 excluded were patients with low tolerability (severe hyperemia (6 patients), discomfort (4), chest pain (1)) and non responders (IOP lowering less than 15% from baseline IOP or target IOP >18 mmHg (4 patients)). Mean IOP at control 1 was 15,92±1,85 mm Hg (21,66% reduction) for 155 patients (non responders excluded), at control 2 was for 155 patients 15,67±2,17 mm Hg (21,14% reduction), and at control 3 for 40 patients 16,28±1,59 mm Hg (19,86% reduction). At control 2 analysis of IOP reduction by 4 groups of previous monotherapy (timolol 0,5% (N=33/66), latanoprost 0,005% (N=49/98), betaxolol 0,5% (N=30/60), and travoprost 0,004% (N=43/85) was performed. 40 patients/79 eyes endured to control 3 (after day 90 free samples were not available for all patients). Analysis of IOP reduction by 4 groups of previous monotherapy medications was performed (timolol 0,5%(N=7/14), latanoprost 0,005% (N=14/28), betaxolol 0,5% (N=7/14), travoprost 0,004% (N=12/23)). Conclusions: Changing patients from prior monotherapy to TTF C can provide on average a further reduction in IOP, while demonstrating a favorable safety profile.CILJ: Zabilježiti sigurnost i učinkovitost promjene antiglaukomske terapije u travoprost 0,004%/timolol 0,5% (TTF C) fiksnu kombinaciju s prethodnih monoterapija. METODE: Prospektivna, otvorena, opservacijska, multicentrična populacija. Promjena s prethodne monoterapije na dan 0 u TTF C, doziran jednom dnevno, ili ujutro ili navečer, bez perioda ispiranja. Aktivno je ocijenjena sistemska i lokalna podnošljivost (popratne pojave), i učinkovitost tj.sniženje intraokularnog tlaka (IOT) na prvoj kontroli (dan 30), drugoj kontroli (dan 90) i trećoj kontroli (dan 120). REZULTATI: 40/155/170 bolesnika (79/309/339 očiju) završilo je studiju (120 dana/ 90 dana/početak). Na prvoj kontroli isključeni su svi bolesnici koji su slabo podnosili lijek: ozbiljna hiperemija (6 bolesnika), neugoda (4), bol u prsištu (1) i ne- responderi tj. sniženje IOT-a manje od 15% od početnog IOT ili ciljnog IOT >18 mmHg (4 bolesnika). Prosječni IOT na prvoj kontroli je bio 15,92±1,85 mm Hg (21,66% sniženja) kod 155 bolesnika (isključeni ne-responderi), na drugoj kontroli je kod 155 bolesnika bio 15,67±2,17 mm Hg (21,14% sniženja), i na trećoj kontroli kod 40 bolesnika 16,28±1,59 mm Hg (19,86% sniženja). Na drugoj kontroli je učinjena analiza sniženja IOT-a u 4 grupe prethodno korištene monoterapije: timolol 0,5% (N=33/66), latanoprost 0,005% (N=49/98), betaxolol 0,5% (N=30/60), i travoprost 0,004% (N=43/85). 40 bolesnika/79 očiju praćeno je do treće kontrole. Učinjena je analiza sniženja IOT-a u 4 grupe prethodno korištene monoterapije: timolol 0,5% (N=7/14), latanoprost 0,005% (N=14/28), betaxolol 0,5% (N=7/14), travoprost 0,004% (N=12/23). Zaključak: Promjena terapije s prethodne monoterapije u TTF C može u prosjeku omogućiti dodatno sniženje IOT-a, uz zadovoljavajući profil sigurnosti

Risk factors for infections caused by carbapenem-resistant Enterobacterales: an international matched case-control-control study (EURECA)

Cases were patients with complicated urinary tract infection (cUTI), complicated intraabdominal (cIAI), pneumonia or bacteraemia from other sources (BSI-OS) due to CRE; control groups were patients with infection caused by carbapenem-susceptible Enterobacterales (CSE), and by non-infected patients, respectively. Matching criteria included type of infection for CSE group, ward and duration of hospital admission. Conditional logistic regression was used to identify risk factors. Findings Overall, 235 CRE case patients, 235 CSE controls and 705 non-infected controls were included. The CRE infections were cUTI (133, 56.7%), pneumonia (44, 18.7%), cIAI and BSI-OS (29, 12.3% each). Carbapenemase genes were found in 228 isolates: OXA-48/like, 112 (47.6%), KPC, 84 (35.7%), and metallo-beta-lactamases, 44 (18.7%); 13 produced two. The risk factors for CRE infection in both type of controls were (adjusted OR for CSE controls; 95% CI; p value) previous colonisation/infection by CRE (6.94; 2.74-15.53; <0.001), urinary catheter (1.78; 1.03-3.07; 0.038) and exposure to broad spectrum antibiotics, as categorical (2.20; 1.25-3.88; 0.006) and time-dependent (1.04 per day; 1.00-1.07; 0.014); chronic renal failure (2.81; 1.40-5.64; 0.004) and admission from home (0.44; 0.23-0.85; 0.014) were significant only for CSE controls. Subgroup analyses provided similar results. Interpretation The main risk factors for CRE infections in hospitals with high incidence included previous coloni-zation, urinary catheter and exposure to broad spectrum antibiotics